EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease

Mario Hero iD, Nadja Grozdanić, Romana Brnić Andrić, Eliša Papić, Olivio Perković, Vladimira Vuletić

Movement Disorders Clinical Practice · 2026

DOI: 10.1002/mdc3.70773 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Mario Hero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Neurology, Clinical Hospital Centre Rijeka, Rijeka, Croatia. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents, Carbidopa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited.

Objectives

To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy.

Methods

Retrospective single‐center observational study of 32 patients initiated on LDp/CDp between April 2024 and January 2026.

Results

Twenty of 32 patients (62.5%) completed 1‐year follow‐up. MDS‐UPDRS Part III improved by 30.3%, Part IV by 36.0% and Part II by 13.2% (all significant); non‐motor and autonomic totals were unchanged. Quality of life improved ( p = 0.040), driven by bodily discomfort. Levodopa‐equivalent dose rose by 31.7% while oral dopamine agonist use fell from 70% to 25% ( p = 0.004).

Conclusions

One year of LDp/CDp was associated with substantial motor benefit and improved quality of life, achieved with higher levodopa equivalent and reduced dopamine agonist use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsCarbidopaHumansMaleFemaleRetrospective StudiesAgedDrug CombinationsQuality of LifeMiddle AgedInfusions, Subcutaneous

Stichwörter der Autor:innen

Parkinson's diseaseautonomic nervous systemhome infusion therapyquality of lifesleep

Substanzen

LevodopaAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug Combinations

Autor:innen und Institutionen

  • Clinic of Neurology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
  • Department of Neurology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.

ORCID-Profile: Mario Hero

Zitieren

APA

Hero, M., Grozdanić, N., Andrić, R. B., Papić, E., Perković, O., & Vuletić, V. (2026). Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70773

Vancouver

Hero M, Grozdanić N, Andrić RB, Papić E, Perković O, Vuletić V. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70773

BibTeX
@article{Hero2026,
  author = {Hero, Mario and Grozdanić, Nadja and Andrić, Romana Brnić and Papić, Eliša and Perković, Olivio and Vuletić, Vladimira},
  title = {Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70773}
}
Kostenlos starten →